Company Not Selling Common Stock via Prospectus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
The company is not selling any shares of common stock pursuant to this prospectus, and will not receive any proceeds from the sale of any shares offered by this prospectus by the selling stockholders.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like CLPT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on CLPT
Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 29.00 USD with a low forecast of 28.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 13.420
Low
28.00
Averages
29.00
High
30.00
Current: 13.420
Low
28.00
Averages
29.00
High
30.00
About CLPT
ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. It provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. It provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. It also offers IRRAflow active fluid-exchange system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ClearPoint Neuro (CLPT) Receives EU MDR Certification for Enhanced Navigation Software Version 3.0.2
- Software Upgrade: ClearPoint Neuro's ClearPoint Navigation Software Version 3.0.2 has received EU MDR certification, introducing an intraoperative CT workflow designed to enhance precision navigation capabilities for neurosurgery in facilities lacking intraoperative MRI, thereby expanding market reach.
- Strong Financial Performance: The company anticipates approximately $10.4 million in revenue for Q4 2025, reflecting a 20% year-over-year growth, with full-year revenue around $37 million and expectations for 2026 revenues between $54 million and $60 million, indicating robust organic growth potential.
- Growing Market Demand: CEO Joe Burnett highlighted a 23% and 26% growth in functional neurosurgery disposables and biologics, respectively, with this growth trend expected to continue into 2026, particularly as the company prepares for the commercial launch of neurocell and gene therapies.
- Mixed Stock Technical Signals: While CLPT stock is currently priced at $16.15, trading 2.9% and 4.1% above its 20-day and 50-day simple moving averages, it remains 11.4% below its 100-day moving average, indicating strong short-term performance but ongoing long-term challenges.
Continue Reading
Booz Allen Hamilton Q3 Earnings Beat Estimates, Shares Up 9.8%
- Earnings Beat: Booz Allen Hamilton reported an adjusted EPS of $1.77 for Q3, surpassing the analyst consensus of $1.29, indicating strong profitability despite a 10.2% year-over-year sales decline.
- Sales Decline: The company's quarterly sales totaled $2.62 billion, missing the street view of $2.75 billion, reflecting challenges in the market environment that may impact future growth strategies.
- Stock Surge: Booz Allen's shares jumped 9.8% to $105.09 on Friday, demonstrating a positive investor reaction to the earnings beat, which bolstered market confidence.
- Mixed Market Performance: While the Dow Jones fell around 200 points, Booz Allen's strong performance contrasted with broader market trends, highlighting stock resilience and selective investor preferences.
Continue Reading